at MarketWatch.com (Jun 6, 2014)
Cardiovascular Systems (CSII +0.4%) says it's enrolled the first patient in Liberty 360 study, a post-market evaluation of the acute and long-term clinical and economic effectiveness of its orbital atherectomy system in treating peripheral arterial disease. The study is unique in that it evaluates success based on long-term outcomes and durability, rather than acute angiographic results of the various treatments.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs